Contract development and manufacturing organisation (CDMO) Onyx Scientific has opened a second facility in North East England, expanding its offerings.
The company’s new site doubles Onyx Scientific’s current footprint and will enable it to expand all Chemistry, Manufacturing and Controls (CMC) activities. The facility will also enable the company to introduce additional GMP facilities that increase capacity for GMP and commercial active pharmaceutical ingredients (API) manufacturing by 50%.
The first phase of the multi-million pound development is now complete and operational with GMP certification and commercial manufacturing approval from the Medicines and Healthcare Products Regulatory Agency (MHRA).
Official comments
Denise Bowser, Commercial Director at Onyx, said: “We are delighted to announce the opening of our new facility in Sunderland. Onyx continues to experience strong growth, driven by the consistent demand from biotech and pharmaceutical companies for integrated early-phase development programmes.
“Our customers recognise the benefits of retaining drug substance activities with one partner and our capability in taking projects from candidate selection to, where appropriate, commercial supply.
“This expansion cements our position as a leading provider of integrated CMC services and drug substance supply and allows us to continue to deliver the exceptional service that we are known for.”
Onyx has grown its workforce by 40% this financial year and now has 100 employees. The company expects a further increase of 50% in the next three years. The final two phases of the new facility are expected to be complete by the end of 2022.
